中肽生化有限公司

Chinese peptide company established on 27 August 2001 and headquartered in the Hangzhou Economic and Technological Development Area in Zhejiang, registered as a wholly foreign invested pharmaceutical manufacturer. Develops and manufactures peptide reagents, pharmaceutical intermediates and nucleic acid drugs and covers the full cycle from early discovery and preclinical research through clinical development to commercial supply as a CRO, CDMO and CMO. Built a large and diverse combinatorial peptide library of more than fifty thousand peptides on its proprietary PeptidEX synthesis technology, passed ISO 9001 certification in 2005, obtained national GMP certification in 2006 and cleared a United States FDA audit with zero deficiencies in 2016. Sells mainly into the United States, Japan and Europe, keeps its international business development centre in Silicon Valley with offices in Boston, Los Angeles, Florida and North Carolina, and is building a modern peptide active ingredient production base in the United States.